Skip to content

Topic

Biotech Venture Funding

Venture capital investment in biotechnology and life-sciences startups, spanning seed to growth-stage rounds, valuations, and funding trends across the sector.

Current stories

investConfirmed3 publishers

Basecamp Research raises more in one round than in its first seven years combined

S32 led a $140M round that takes Basecamp Research's total funding to $225M since 2019. Two of the sixteen named backers, NVIDIA and Anthropic's Anthology Fund, are also partners on the dataset its models train on.

Perspective Coverage

3 publishers
Builder
Builder 30%
Operator
Operator 15%
Investor
Investor 55%

Reality

Evidence55
Adoption
Not scored
Hype gap+40
Incentives75
Confidence60
scienceOne report1 publisher

Obvious Ventures led $20M behind Mithrl's promise of a 50% faster path to IND

The Series A funds a second-generation platform. The only measured result the company has attached to it is a benchmark of its own showing 45% fewer tokens than uncustomized frontier models. Tokens are a compute cost.

Publishers:genengnews.com

Reality

Evidence32
Adoption24
Hype gap+42
Incentives78
Confidence60
scienceOne report1 publisher

Massachusetts biotech: growth-stage money is back, seed money and NIH awards are not

MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.

Publishers:genengnews.com

Reality

Evidence61
Adoption58
Hype gap+12
Incentives74
Confidence63
productOne report1 publisher

Vivodyne says the AI drug bottleneck is human tissue data, not model capability

The startup opened what it calls the world's largest human data center last week. Its diagnosis of the field is testable; most of the evidence for its own machines is self-reported.

Publishers:techcrunch.com

Reality

Evidence34
Adoption27
Hype gap+32
Incentives76
Confidence44